Repartition and outcome per ALFA decision tool tier in the ALFA1200 training cohort and validation cohorts
| . | Training cohort . | Validation cohorts . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALFA1200 (n = 471) . | AMLSG (n = 223) . | HDF (n = 141) . | SAL (n = 466) . | |||||||||
| n (%) . | 2-y OS (95% CI) . | P . | n (%) . | 2-y OS (95% CI) . | P . | n (%) . | 2-y OS (95% CI ) . | P . | n (%) . | 2-y OS (95% CI) . | P . | |
| Go-go* | 184 (39.1) | 66.1% (59.5-73.3) | <10−5 | 84 (37.7) | 44.8 (35.3-56.9) | .0006 | 44 (31.2) | 43.4 (30.7-61.4) | .06 | 171 (36.7) | 35.5 (28.9-43.5) | .02 |
| Slow-go | 251 (53.3) | 39.1% (33.5-45.7) | Ref. | 113 (50.7) | 21.9 (15.4-31.2) | Ref. | 78 (55.3) | 29.9 (21.2-42.2) | Ref. | 243 (52.1) | 28.2 (20.1-31.2) | Ref. |
| No-go | 36 (7.6) | 2.8% (0.4-19.2) | <10−5 | 26 (11.6) | 3.8 (0.5-26.2) | 3 × 10−5 | 19 (13.5) | 10.5 (2.8-39.1) | .01 | 52 (11.2) | 2.0 (0.2-13.9) | <10−5 |
| Overall log-rank test | <10−5 | <10−5 | .003 | <10−5 | ||||||||
| . | Training cohort . | Validation cohorts . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALFA1200 (n = 471) . | AMLSG (n = 223) . | HDF (n = 141) . | SAL (n = 466) . | |||||||||
| n (%) . | 2-y OS (95% CI) . | P . | n (%) . | 2-y OS (95% CI) . | P . | n (%) . | 2-y OS (95% CI ) . | P . | n (%) . | 2-y OS (95% CI) . | P . | |
| Go-go* | 184 (39.1) | 66.1% (59.5-73.3) | <10−5 | 84 (37.7) | 44.8 (35.3-56.9) | .0006 | 44 (31.2) | 43.4 (30.7-61.4) | .06 | 171 (36.7) | 35.5 (28.9-43.5) | .02 |
| Slow-go | 251 (53.3) | 39.1% (33.5-45.7) | Ref. | 113 (50.7) | 21.9 (15.4-31.2) | Ref. | 78 (55.3) | 29.9 (21.2-42.2) | Ref. | 243 (52.1) | 28.2 (20.1-31.2) | Ref. |
| No-go | 36 (7.6) | 2.8% (0.4-19.2) | <10−5 | 26 (11.6) | 3.8 (0.5-26.2) | 3 × 10−5 | 19 (13.5) | 10.5 (2.8-39.1) | .01 | 52 (11.2) | 2.0 (0.2-13.9) | <10−5 |
| Overall log-rank test | <10−5 | <10−5 | .003 | <10−5 | ||||||||
P values by overall log-rank test and from pairwise log-rank tests considering the slow-go group as reference (Ref.)
Go-go tier: non–poor cytogenetics, NPM1 mutated and at most 1 mutation among FLT3-ITD low, DNMT3A, ASXL1, or NRAS OR non–poor cytogenetics and NPM1, FLT3-ITD, DNMT3A, ASXL1, and NRAS all wild-type; no-go tier: poor-risk cytogenetic with KRAS and/or TP53 mutation; slow-go: all others.